Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Our approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant. VI became shareholder of Cell Medica through its acquisition of Delenex Therapeutics. Delenex was a biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics with applications in immunotherapy in improving CAR-T cells and as TCR-like antibodies.

Menu